{"filing":{"accession_number":"0001213900-26-076715","cik":"0001946563","ticker":"SXTPW","company_name":"60 DEGREES PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"ea0297549-8k_60degrees.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026076715/ea0297549-8k_60degrees.htm"},"events":[{"id":16827,"run_id":15054,"accession_number":"0001213900-26-076715","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure describes a clinical trial milestone—preparation of a statistical analysis plan (SAP) for an interim analysis of a Phase 2/3 randomized, placebo-controlled trial of tafenoquine in severe babesiosis, with 23 of 33 planned patients enrolled as of the filing date. This is a material operational and regulatory development for a clinical-stage biopharmaceutical company, as it outlines the pathway toward potential FDA submission and a Commissioner's National Priority Review Voucher application by Q1 2028. The event is clearly operational/strategic (clinical development progress) rather than financial, governance, legal, or existential in nature, and does not fit a more specific category.","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15039,"accession_number":"0001213900-26-076715","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes a clinical trial milestone—preparation of a statistical analysis plan (SAP) for an interim analysis of a Phase 2/3 randomized, placebo-controlled trial of tafenoquine in severe babesiosis, with 23 of 33 planned patients enrolled as of the filing date. This is a material operational and regulatory development for a clinical-stage biopharmaceutical company, as it outlines the pathway toward potential FDA submission and a Commissioner's National Priority Review Voucher application by Q1 2028. The event is clearly operational/strategic (clinical development progress) rather than financial, governance, legal, or existential in nature, and does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:36:14.189647+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15039,"accession_number":"0001213900-26-076715","item_number":"8.01","item_title":"Other Events","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure describes a clinical trial milestone—preparation of a statistical analysis plan (SAP) for an interim analysis of a Phase 2/3 randomized, placebo-controlled trial of tafenoquine in severe babesiosis, with 23 of 33 planned patients enrolled as of the filing date. This is a material operational and regulatory development for a clinical-stage biopharmaceutical company, as it outlines the pathway toward potential FDA submission and a Commissioner's National Priority Review Voucher application by Q1 2028. The event is clearly operational/strategic (clinical development progress) rather than financial, governance, legal, or existential in nature, and does not fit a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:36:14.189647+00:00","company_name":"60 DEGREES PHARMACEUTICALS, INC.","ticker":"SXTPW","filing_date":"2026-07-09"}]}